Indications for and questions about antenatal steroids

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Pharmacology

Background:

• Antenatal glucocorticoid treatment is standard care for preterm delivery risk since 1994.
• Evidence supports its use in specific conditions like prolonged rupture of membranes, very early gestations, and preeclampsia.
• Chronic silent chorioamnionitis is not a contraindication for this therapy.

Purpose of the Study:

• To review the current evidence and recommendations for antenatal glucocorticoid therapy.
• To clarify indications, contraindications, and optimal treatment regimens.
• To assess the safety and efficacy of antenatal glucocorticoids.

Main Methods:

• Review of existing literature and clinical guidelines.
• Analysis of data on treatment efficacy and adverse effects.
• Synthesis of current expert opinion on antenatal glucocorticoid use.

Main Results:

• A single course of antenatal glucocorticoids is highly effective in improving neonatal outcomes.
• The preferred regimen involves a combination of short- and long-acting betamethasone.
• Repeated courses are not indicated, and no adverse effects from a single course have been identified.

Conclusions:

• Antenatal glucocorticoid therapy is a crucial intervention for pregnancies at risk of preterm birth.
• The established treatment protocol is safe and effective for improving neonatal survival and reducing complications.
• Continued adherence to guidelines ensures optimal benefits for mother and neonate.